Search research articles
Contact Us
Filters
Showing results (21-30 of 58) with videos related to
Page
of 6
Sort By:
Journal of Cancer Research and Clinical Oncology
|
January 1, 1995
In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors
E Huland, B Falk, D Hübner, et al.
The Journal of Urology
|
September 1, 1992
Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder
H Heinzer, E Huland, M Mönk, et al.
Anticancer Research
|
September 2, 1999
Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure
A Haese, E Huland, M Graefen, et al.
Urology
|
January 1, 1995
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer
E Huland, H Schwaibold, R Klän, et al.
The Cancer Journal From Scientific American
|
February 24, 2000
Overview of interleukin-2 inhalation therapy
E Huland, H Heinzer, H Huland, et al.
Der Urologe. Ausg. A
|
September 29, 1999
[Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter]
H Heinzer, E Huland, M Aalamian, et al.
The Journal of Urology
|
March 1, 1991
Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma
R Klän, E Huland, H Baisch, et al.
The Cancer Journal From Scientific American
|
February 11, 1998
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience
E Huland, H Heinzer, T S Mir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy
H Heinzer, T S Mir, E Huland, et al.
The Journal of Urology
|
April 1, 1996
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies
H Huland, P Hammerer, R P Henke, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 58) with videos related to
Sort By:
Page
of 6
Journal of Cancer Research and Clinical Oncology
|
January 1, 1995
In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors
E Huland, B Falk, D Hübner, et al.
The Journal of Urology
|
September 1, 1992
Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder
H Heinzer, E Huland, M Mönk, et al.
Anticancer Research
|
September 2, 1999
Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure
A Haese, E Huland, M Graefen, et al.
Urology
|
January 1, 1995
Long-term monitoring of 486P 3/12 antigen pattern (quantitative immunocytology) before, during, and after mitomycin C prophylaxis in patients with superficial bladder cancer
E Huland, H Schwaibold, R Klän, et al.
The Cancer Journal From Scientific American
|
February 24, 2000
Overview of interleukin-2 inhalation therapy
E Huland, H Heinzer, H Huland, et al.
Der Urologe. Ausg. A
|
September 29, 1999
[Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter]
H Heinzer, E Huland, M Aalamian, et al.
The Journal of Urology
|
March 1, 1991
Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486 P3/12 in 241 unselected patients with bladder carcinoma
R Klän, E Huland, H Baisch, et al.
The Cancer Journal From Scientific American
|
February 11, 1998
Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience
E Huland, H Heinzer, T S Mir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy
H Heinzer, T S Mir, E Huland, et al.
The Journal of Urology
|
April 1, 1996
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies
H Huland, P Hammerer, R P Henke, et al.
Page
of 6